Progesterone News and Research

RSS

Fewer babies face health risks of early birth

The nation's preterm birth rate dropped for the second consecutive year.

7 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Traces of many medicines found in fish swimming in treated waste water

Researchers at Ume- University and the Sahlgrenska Academy at the University of Gothenburg, Sweden, have discovered that traces of many medicines can be found in fish that have been swimming in treated waste water. One such medicine, the hormone levonorgestrel, was found in higher concentrations in the blood of fish than in women who take the contraceptive pill. Elevated levels of this hormone can lead to infertility in fish.

5 Apr 2010

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Healthy pre-and post-menopausal Japanese women who took a supplement of SE5-OH containing Natural S-equol, a novel soy germ-based ingredient under development for the management of menopausal symptoms, had measures of reproductive hormones that stayed within normal limits throughout the study.

3 Apr 2010

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced that it has signed a co-promotion agreement for Zipsor™ (diclofenac potassium) Liquid Filled Capsules with Ferring Pharmaceuticals Inc., a global bio-pharmaceutical company, headquartered in Switzerland.

1 Apr 2010

Link between occupational exposures and postmenopausal breast cancer

Occupational exposure to certain chemicals and pollutants before a woman reaches her mid-30s could treble her risk of developing cancer after the menopause, suggests research published in Occupational and Environmental Medicine .

1 Apr 2010

Presence of PARP protein in tumours can help predict their response to chemotherapy

The presence of the protein poly polymerase in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference in Barcelona tomorrow (Saturday 27 March).

27 Mar 2010

Presence of protein PARP in tumours may help predict response to chemotherapy

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to current belief that PARP is associated with a limited number of tumours, he and his team found for the first time that PARP expression exists across all breast cancer subtypes, and that such tumours were highly sensitive to chemotherapy.

26 Mar 2010

Complex relation between breastfeeding, prolactin and breast cancer

Women who are diagnosed with breast cancer in the 12 months after they have completed a pregnancy are 48% more likely to die than other young women with breast cancer according to new research to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday).

26 Mar 2010

Pregnancy safe for breast cancer survivors, says study

Women who have been treated for breast cancer can choose to become pregnant and have babies, without fears that pregnancy could put them at higher risk of dying from their cancer, according to a major, new study.

26 Mar 2010

Palex Medical to distribute Genomic Health's Oncotype DX breast cancer test in Spain and Portugal

Genomic Health, Inc. today announced that the company has entered into an exclusive agreement with Palex Medical S.A., one of Europe's leading distributors of medical device and diagnostic services to hospitals, to distribute its Oncotype DX® breast cancer test in Spain and Portugal. The distribution agreement, announced in conjunction with positive data presented today at the 7th European Breast Cancer Conference (EBCC), further expands the global presence of Oncotype DX, providing for increased physician and patient access to this advanced diagnostic test in the European market.

26 Mar 2010

BHR Pharma salutes BIAA's efforts to raise awareness on concussion

BHR Pharma salutes the Brain Injury Association of America for its concerted efforts to raise awareness about the dangers and proper treatment of concussions everywhere from playgrounds to professional sports arenas. BIAA is correctly pointing out through its advocacy that concussions are TBIs, with the potential for serious, debilitating and long-term effects.

24 Mar 2010

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

Columbia Laboratories, Inc. today reported financial results of the three- and twelve-months periods ended December 31, 2009.

11 Mar 2010

Iraqi National Cancer Research Program established to curb rising incidence of breast cancer

Breast cancer continues to rise in Iraq, and scientists have established the Iraqi National Cancer Research Program to better understand the underlying molecular and environmental causes in an effort to curb the incidence of cancer.

11 Mar 2010

Positive results from international study of Oncotype DX breast cancer RS

Genomic Health, Inc. today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either anastrozole or tamoxifen.

9 Mar 2010

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Findings could lead to new cancer-fighting drugs

A new study is providing insight into how estrogen fuels many breast cancers, and researchers say the findings could lead to new cancer-fighting drugs.

3 Mar 2010

My Little Miracle Essay Contest: Winners to receive education fund prizes to support their children's future

If you are a parent who has conceived using Ferring Pharmaceuticals' fertility products, you can win a $10,000 education fund to support your child's future. Two other education fund prizes will also be awarded.

2 Mar 2010

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

A newly identified cancer biomarker could define a new subtype of breast cancer as well as offer a potential way to treat it, say researchers at Washington University School of Medicine in St. Louis. Their findings will be published in the March 1 online early edition issue of the Proceedings of the National Academy of Sciences.

2 Mar 2010

Progesterone News and Research

Fewer babies face health risks of early birth

StockPreacher.com releases investment report on Repros Therapeutics

Traces of many medicines found in fish swimming in treated waste water

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Link between occupational exposures and postmenopausal breast cancer

Presence of PARP protein in tumours can help predict their response to chemotherapy

Presence of protein PARP in tumours may help predict response to chemotherapy

Complex relation between breastfeeding, prolactin and breast cancer

Pregnancy safe for breast cancer survivors, says study

Palex Medical to distribute Genomic Health's Oncotype DX breast cancer test in Spain and Portugal

BHR Pharma salutes BIAA's efforts to raise awareness on concussion

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

Iraqi National Cancer Research Program established to curb rising incidence of breast cancer

Positive results from international study of Oncotype DX breast cancer RS

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Findings could lead to new cancer-fighting drugs

My Little Miracle Essay Contest: Winners to receive education fund prizes to support their children's future

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News